The latest price target for Pharvaris (NASDAQ:PHVS) was reported by Oppenheimer on September 6, 2024. The analyst firm set a price target for $42.00 expecting PHVS to rise to within 12 months (a possible 107.41% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Pharvaris (NASDAQ:PHVS) was provided by Oppenheimer, and Pharvaris maintained their outperform rating.

The last upgrade for Pharvaris NV happened on August 15, 2023 when Morgan Stanley raised their price target to $34. Morgan Stanley previously had an equal-weight for Pharvaris NV.

The last downgrade for Pharvaris NV happened on August 23, 2022 when Morgan Stanley changed their price target from $40 to $10 for Pharvaris NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pharvaris, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pharvaris was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

While ratings are subjective and will change, the latest Pharvaris (PHVS) rating was a maintained with a price target of $38.00 to $42.00. The current price Pharvaris (PHVS) is trading at is $20.25, which is out of the analyst’s predicted range.